10 terminated, 4 completed, 1 active not recruiting, 1 recruiting. 15 Phase 2, 4 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 15 | Terminated 10, Completed 3, Recruiting 1, Withdrawn 1 |
| Phase 1 | 4 | Active not recruiting 1, Completed 1, Terminated 1, Withdrawn 1 |
Follow CYT107: new trials by email Literature Review of CYT107 trials Research Report on CYT107
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Recombinant Glycosylated Human Interleukin-7 (CYT107) for the Treatment of Kaposi Sarcoma in Participants With HIV and Immune Non-Response (REGIMENKS HIV) CYT107 - Kaposi Sarcoma | Phase 2 | Recruiting | National Cancer Institute (NCI) | 55 | 2026-04-08 | 2026-08-25 |
| Impact of Recombinant Human Interleukin-7 (CYT107) on Tumor Clearance and Immune Reconstitution in Multiple Myeloma Patients After Autologous Hematopoietic Cell Transplant Recombinant glycosylated human interleukin-7, Melphalan, Autologous hematopoietic cell transplant - Multiple Myeloma | Phase 1 | Active not recruiting | Washington University School of Medicine | 30 | 2025-04-04 | 2026-09-01 |
| InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection (Brazil Cohort) Interleukin-7, PLACEBO - COVID-19, Lymphocytopenia | Phase 2 | Terminated | Revimmune | 4 | 2021-03-01 | 2024-04-12 |
| InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic Patients With COVID-19 Infection ( ILIAD-7-US-O ) CYT107, Placebo - COVID-19, Lymphocytopenia | Phase 2 | Terminated | Revimmune | 10 | 2020-12-20 | 2024-04-11 |
| Recombinant Interleukin-7 (CYT107) to Treat Patients With Refractory Nontuberculous Mycobacterial Lung Disease Recombinant human interleukin-7 - Mycobacterium Infections, Nontuberculous | Phase 2 | Terminated | Revimmune | 8 | 2020-11-30 | 2024-04-11 |
| InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection ( ILIAD-7-US-I ) CYT107, Placebo - COVID-19, Lymphocytopenia | Phase 2 | Terminated | Revimmune | 26 | 2020-09-15 | 2022-04-08 |
| InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection FR BL Cohort Interleukin-7, Placebo - COVID-19, Lymphocytopenia | Phase 2 | Terminated | Revimmune | 34 | 2020-06-08 | 2022-04-08 |
| InterLeukin-7 (CYT107) to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection UK Cohort Interleukin-7, Placebos - COVID-19, Lymphocytopenia | Phase 2 | Terminated | Revimmune | 35 | 2020-05-14 | 2022-04-07 |
| Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma Atezolizumab, Biopsy, Biospecimen Collection - Advanced Bladder Urothelial Carcinoma, Advanced Ureter Urothelial Carcinoma | Phase 2 | Completed | National Cancer Institute (NCI) | 47 | 2019-06-05 | 2024-07-26 |
| Recombinant Interleukin-7 (CYT107) to Restore Absolute Lymphocyte Counts in Sepsis Patients CYT107, Placebos - Sepsis, Severe | Phase 2 | Terminated | Revimmune | 21 | 2019-06-01 | 2021-10-27 |
| Recombinant Human Interleukin-7 (CYT107) to Promote T-Cell Recovery After Cord Blood Transplantation CYT107 - Umbilical Cord Blood Transplant | Phase 1 / Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2018-11-01 | 2019-01-10 | |
| A Study of IL-7 to Restore Absolute Lymphocyte Counts in Sepsis Patients Interleukin-7, Placebo - Severe Sepsis With Septic Shock | Phase 2 | Completed | Revimmune | 27 | 2016-01-01 | 2020-07-09 |
| CYT107 After Vaccine Treatment (Provenge®) in Patients With Metastatic Castration-Resistant Prostate Cancer Glycosylated Recombinant Human Interleukin-7, Laboratory Biomarker Analysis - Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma | Phase 2 | Completed | Fred Hutchinson Cancer Center | 54 | 2013-09-10 | 2019-07-09 |
| Randomized Study on Multiple Cycles of Interleukin-7 in HIV Patients Immune Non-responders CYT107 - HIV | Phase 2 | Terminated | Cytheris SA | 92 | 2010-09-01 | 2013-07-25 |
| Study on Interleukin-7 (CYT107) in HIV Patients Interleukin-7 - HIV | Phase 2 | Terminated | Cytheris SA | 23 | 2010-01-01 | 2013-08-01 |
| Interleukin-7 (CYT107) Treatment of Idiopathic CD4 Lymphocytopenia: Expansion of CD4 T Cells (ICICLE) CYT107 - Idiopathic CD4+ T-Lymphocytopenia | Phase 1 / Phase 2 | Terminated | National Institute of Allergy and Infectious Diseases (NIAID) | 21 | 2009-02-01 | 2015-10-15 |
| Safety Study of IL-7 in HIV-infected Patients (Inspire) CYT 107 - HIV Infections, Lymphopenia | Phase 1 | Completed | Cytheris SA | 30 | 2007-05-01 | 2012-10-18 |
Lymphopenia (7) · COVID-19 (5) · Carcinoma, Transitional Cell (1) · Communicable Diseases (1) · HIV Infections (1) · Lymphoproliferative Disorders (1) · Multiple Myeloma (1) · Mycobacterium Infections, Nontuberculous (1) · Neoplasms, Plasma Cell (1) · Prostatic Neoplasms (1) · Sarcoma, Kaposi (1) · Sepsis (1) · T-Lymphocytopenia, Idiopathic CD4-Positive (1) · Ureteral Neoplasms (1) · Urethral Neoplasms (1)
Revimmune (8) · Cytheris SA (3) · National Cancer Institute (NCI) (2) · Fred Hutchinson Cancer Center (1) · M.D. Anderson Cancer Center (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · Washington University School of Medicine (1)
United States (12) · France (3) · Canada (2) · Italy (2) · Brazil (1) · South Africa (1) · Switzerland (1) · United Kingdom (1)
David Marin, MD (1) · Dilan A Patel, M.D. (1) · Evan Y Yu (1) · Irini Sereti (1) · Lawrence Fong (1) · Manu Shankar-Hari, MD PhD (1) · Marcel van den Brink, MD, PhD (1) · Martin A. Cheever (1) · Michael Lederman (1) · Michael M. Lederman,, Pr (1) · Ramya M Ramaswami, M.D. (1)
PMID 39903535, PMID 29515037, PMID 32031570, PMID 32171076, PMID 23053510, PMID 26908786, PMID 12519925, PMID 18946659, PMID 19287090, PMID 19424209, PMID 21153402, PMID 21508983, PMID 22187279, PMID 22383042, PMID 22693226, PMID 23427891, PMID 24232462, PMID 26675348, PMID 36906875, PMID 40351870
P30CA015704 (2), U01CA154967 (2), P50CA097186 (1), R01CA061508 (1)